Murali Matta

Dr. Murali Matta

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JLJunyi Li
Junyi Li
JFJeffry Florian
Jeffry Florian
ECElizabeth Campbell
Elizabeth Campbell
SSSarah J. Schrieber
Sarah J. Schrieber
JBJane P.F. Bai
Jane P.F. Bai
DSDavid G. Strauss
David G. Strauss
Click on the article title to read more.

1 March 2018 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
DSDerek Schocken
Derek Schocken
JSJayna Stohlman
Jayna Stohlman
JVJose Vicente
Jose Vicente
DCDulciana Chan
Dulciana Chan
DPDakshesh Patel
Dakshesh Patel
KBKsenia Blinova
Ksenia Blinova

28 September 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
ACAshok Chockalingam
Ashok Chockalingam
SSSharron Stewart
Sharron Stewart
LXLin Xu
Lin Xu
AGAdarsh Gandhi
Adarsh Gandhi
MMMurali Matta
Murali Matta
RRRodney Rouse
Rodney Rouse
Urinary tract infections (UTI) are common worldwide and are becoming increasingly difficult to treat because of the development of antibiotic resistance. Immunocompetent murine models of human UTI have been used to study pathogenesis and treatment but not for investigating resistance development after treatment with antibiotics. In this study, intravesical inoculation of uropathogenic Escherichia coli CFT073 in immunocompetent Balb/c mice was used as a model of human UTI. The value of the model in investigating antibiotic exposure on in vivo emergence of antibiotic resistance was examined. Experimentally infected mice were treated with 20 or 200 mg/kg ampicillin, 5 or 50 mg/kg ciprofloxacin, or 100 or 1000 mg/kg of fosfomycin. Ampicillin and ciprofloxacin were given twice daily at 8 h intervals, and fosfomycin was given once daily. Antibiotic treatment began 24 h after bacterial inoculation and ended after 72 h following the initial treatment. Although minimum inhibitory concentrations (MIC) for the experimental strain of E. coli were exceeded at peak concentrations in tissues and consistently in urine, low levels of bacteria persisted in tissues in all experiments. E. coli from bladder tissue, kidney, and urine grew on plates containing 1× MIC of antibiotic, but none grew at 3× MIC. This model is not suitable for studying emergent resistance but might serve to examine bacterial persistence.

29 January 2018 in Analytical Methods
Verified
Journal Article
Closed access
PDF file
MMMurali Matta
Murali Matta
ACAshok Chockalingam
Ashok Chockalingam
AGAdarsh Gandhi
Adarsh Gandhi
SSSharron Stewart
Sharron Stewart
LXLin Xu
Lin Xu
RRRodney Rouse
Rodney Rouse
The authors proposed a simple, high throughput liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of ciprofloxacin in small sample volumes of plasma, urine, bladder and kidneys of mice. d8-Ciprofloxacin was used as an internal standard (IS) which efficiently tracked the matrix effect in different matrices. The method employed 20 μL of plasma/30 μL of urine or tissue homogenate for sample processing using a simple protein precipitation technique. The processed samples were chromatographed on a C18 column by using a mixture of 5 mM ammonium formate (0.1% formic acid)–acetonitrile as the mobile phase at a flow rate of 0.6 mL min−1 with a gradient elution for 3 min. The calibration curve obtained was linear over the concentration range of 100–5000 ng mL−1 with r2 ≥ 0.99 in all matrices. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. The multiple reaction-monitoring mode (MRM) was used for the quantification of ion transitions at m/z 332.1/230.8 and 340.1/296.1 for the analyte and the IS, respectively. The validated method was used for preclinical studies of antimicrobial resistance in mice.

2 December 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JFJeffry Florian
Jeffry Florian
VGVictoria Gershuny
Victoria Gershuny
QSQin Sun
Qin Sun
SSSarah J. Schrieber
Sarah J. Schrieber
MMMurali Matta
Murali Matta
DSDavid G. Strauss
David G. Strauss

15 November 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MSMorasa Sheikhy
Morasa Sheikhy
SSSarah J. Schrieber
Sarah J. Schrieber
QSQin Sun
Qin Sun
VGVictoria Gershuny
Victoria Gershuny
MMMurali Matta
Murali Matta
JFJeffry Florian
Jeffry Florian